SCHEMBL174815

SCHEMBL174815

CC1(OC(=O)CC(=O)OC2(C)CNCCc3ccccc32)CNCCc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.40
HTR2C P28335 4/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
DRD2 P14416 2/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
KDM1A O60341 1/20 0.33
HTR2B P41595 1/20 0.33
PNMT P11086 1/20 0.33
CD44 P16070 1/20 0.33
MAOB P27338 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
BRD4 O60885 1/20 0.33
HDAC9 Q9UKV0 1/20 0.33
DRD1 P21728 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL173574 0.91 HTR2A (0.39) HTR2AHTR2CMEN1KMT2ADRD2
SCHEMBL173679 0.90 HTR2A (0.38) HTR2AHTR2CMEN1KMT2ADRD2
SCHEMBL174416 0.84 HTR2A (0.40) HTR2AHTR2CMEN1KMT2ADRD2
SCHEMBL175131 0.84 HTR2A (0.40) HTR2AHTR2CMEN1KMT2ADRD2
SCHEMBL173952 0.83 HTR2A (0.57) HTR2AHTR2CSLC6A2SLC6A4KDM1A
SCHEMBL175226 0.81 SLC13A5 (0.36) HTR2AMEN1KMT2A
SCHEMBL174565 0.81 KIF11 (0.34) HTR2AHTR2CMEN1KMT2ADRD2
SCHEMBL174886 0.77 HTR2A (0.41) HTR2AHTR2CMEN1KMT2ADRD2
SCHEMBL173622 0.75 HTR2A (0.57) HTR2AHTR2CSLC6A2SLC6A4KDM1A
SCHEMBL174877 0.75 CYP1A2 (0.42) HTR2AHTR2CMEN1KMT2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611449-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT Arena Pharmaceuticals, Inc. (US) 2013-07-10 EP disclosed
WO-2012030939-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT ARENA PHARMACEUTICALS, INC. (US) 2012-03-08 WO disclosed